GlassScriptPhysician profile
Zhora Oganisyan
NPI 1508126624
$17,796.50
in general payments reported to CMS, 2019-2025
67 companies · $1,659 in 2025
The $1,659 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $1,226 · 2021: $2,635 · 2022: $3,649 · 2023: $3,747 · 2024: $2,927 · 2025: $1,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,333.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,035.89 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,168.96 | 2019-2025 | |
| Ge Healthcare | $923.62 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $823.34 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $767.69 | 2019-2024 | Ajovy, Austedo, Austedo Xr |
| Sk Life Science, INC. | $764.77 | 2021-2025 | Xcopri |
| Allergan, INC. | $760.32 | 2019-2022 | |
| Amgen INC. | $678.10 | 2019-2025 | Uplizna, Aimovig |
| Genzyme Corporation | $598.24 | 2019-2023 | |
| Ucb, INC. | $563.61 | 2019-2025 | Zilbrysq, Briviact, Fintepla |
| Eisai INC. | $551.79 | 2019-2025 | |
| Pfizer INC. | $536.85 | 2022-2025 | |
| Celgene Corporation | $534.36 | 2020-2025 | Zeposia |
| Biogen, INC. | $533.11 | 2019-2025 | Vumerity |
| Emd Serono, INC. | $488.47 | 2019-2025 | Mavenclad |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhora Oganisyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.